Modulation of antitumor alkylating agents (AA).
Teicher
B A
BA
Frei
E
E
D000477:Alkylating Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D015687:Cell Hypoxia; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004249:DNA Damage; D004260:DNA Repair / Q000187:drug effects; D004338:Drug Combinations; D004347:Drug Interactions; D004351:Drug Resistance; D005466:Fluorocarbons / Q000494:pharmacology; D005978:Glutathione / Q000378:metabolism; D005982:Glutathione Transferase / Q000378:metabolism; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives; D007191:Indazoles / Q000494:pharmacology; D008668:Metallothionein / Q000378:metabolism; D009363:Neoplasm Proteins / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009593:Nitroimidazoles / Q000494:pharmacology; D010100:Oxygen / Q000494:pharmacology; D011838:Radiation-Sensitizing Agents / Q000494:pharmacology; D059005:Topoisomerase II Inhibitors; D014970:Xanthines / Q000494:pharmacology
D000477:Alkylating Agents; D000970:Antineoplastic Agents; D004338:Drug Combinations; D005466:Fluorocarbons; D006895:Hydroxyethyl Starch Derivatives; D007191:Indazoles; D009363:Neoplasm Proteins; D009593:Nitroimidazoles; D011838:Radiation-Sensitizing Agents; D059005:Topoisomerase II Inhibitors; D014970:Xanthines; C008514:methylxanthine; C017323:glucose, glycerol, hydroxyethyl starch, perfluorodecalin, perfluorotripropylamine, pluronic F-68, salts, yolk phospholipids drug combination; D008668:Metallothionein; D005982:Glutathione Transferase; D005978:Glutathione; D002945:Cisplatin; D010100:Oxygen; C016371:lonidamine